Session 9

The evolving expectations and contributions of patients in the medicines’ innovation ecosystem

Organised by the European Medicines Agency

The pharmaceutical landscape is rapidly evolving, with patients moving from passive recipients to active collaborators throughout the medicines’ development continuum. The paradigm shifts from developing treatments “for patients” to co-creating them “with patients,” integrating patient preferences and real-world data. The enhanced patient involvement from early stages of medicine lifecycle, in clinical trial design, endpoint selection, and regulatory decision-making shapes a change of paradigm.

This session will explore the role of patients in medicines development, assessment and post-authorisation and look into the future where digital technologies and artificial intelligence could further enable a dynamic relationship between patients, regulators, and the pharmaceutical industry, fundamentally reshaping how medicines are developed, evaluated, monitored, accessed, and used.

Speakers to be announced